- Home
- LPRO vs ALDX Comparison
LPRO vs ALDX Comparison
Compare LPRO & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LPRO | ALDX |
|---|---|---|
| Founded | 2000 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.9M | 293.0M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | LPRO | ALDX |
|---|---|---|
| Price | $1.69 | $4.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | $2.83 | ★ $9.50 |
| AVG Volume (30 Days) | 541.8K | ★ 971.9K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,948,000.00 | N/A |
| Revenue This Year | $306.66 | N/A |
| Revenue Next Year | $7.97 | $36.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.70 | $1.14 |
| 52 Week High | $6.75 | $7.20 |
Technical Indicators
Market Signals| Indicator | LPRO | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 45.69 | 31.41 |
| Support Level | $1.77 | $4.67 |
| Resistance Level | $1.81 | $4.91 |
| Average True Range (ATR) | 0.09 | 0.31 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 15.63 | 0.63 |
Price Performance
Historical ComparisonAbout LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.